Algiax Pharma Reports Promising Phase 2a Results for AP-325

Algiax Pharmaceuticals, a biotech company in the clinical stage that specializes in creating innovative therapies for chronic neuropathic pain, revealed promising topline results from its phase 2a clinical trial assessing AP-325 for neuropathic pain treatment. The research showed that the company’s leading candidate can swiftly alleviate neuropathic pain and provide enduring advantages for patients after treatment.

AP-325 is a small molecule that is non-opioid and targets neuropathic pain reduction by stimulating GABAA signaling. Neuropathic pain is a persistent condition frequently linked to an imbalance between excitatory and inhibitory neuronal signals. By consistently inhibiting the overactivation of neurons, AP-325 could transform the management of neuropathic pain.

"These findings represent a major advancement towards our goal of alleviating chronic neuropathic pain and providing a safe treatment alternative free from dependency risk for patients enduring this challenging condition," stated Dr. Ingo Lehrke, CEO of Algiax Pharmaceuticals. "Given these very promising outcomes, we are investigating the optimal way to swiftly provide the advantages of AP-325 to individuals enduring chronic pain globally and enhance their quality of life."

The phase 2a randomized, double-blinded, placebo-controlled study assessed the safety and effectiveness of AP-325 used alone in individuals suffering from peripheral post-surgical neuropathic pain. The research included 99 individuals from Germany, Spain, the Czech Republic, Belgium, and France across 27 different locations.